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We have examined both the sequence changes in the LTR, gag, vif, vpr, vpx, tat, rev, vpu, env, and nef genes and the cell
tropism of a cell-free stock of chimeric simian–human immunodeficiency virus (SHIV) isolated from the cerebrospinal fluid
of a pig-tailed macaque (PNb) that developed AIDS. This virus (SHIVKU-1) is highly pathogenic when inoculated into other
macaques. DNA sequence analysis of PCR-amplified products revealed a total of 5 nucleotide changes in the LTR while vif
had 2 consensus amino acid changes. The gag, vif, and vpx had no consensus amino acid substitutions, whereas vpr had
1 consensus substitution. The tat and rev genes of the HXB2 region of SHIVKU-1 had 2 and 1 consensus amino acid changes,
respectively. The vpu gene of the HXB2 region of SHIV, which originally had an ACG codon at the beginning of the gene,
reverted to an initiation ATG codon and in addition contained a consensus amino acid substitution at position 69 of this
protein. As expected, the majority of the nucleotide substitutions were found in the env and nef genes. Thirteen and 5 amino
acid changes were predicted for the corresponding Env and Nef proteins, respectively. In addition, one-third of the env
gene clones isolated from the SHIVKU-1 stock had a 5-amino-acid deletion in the V4 region. Using three independent
assays, we determined that the changes in the SHIVKU-1 were associated with an increase in the efficiency of replication
in macrophages. The strikingly few consensus changes in the virus suggest that conversion of this virus to one capable of
causing AIDS in pig-tailed macaques was associated with relatively few changes in the viral envelope and/or accessory
genes. These results will provide the basis for the development of a pathogenic, molecular clone of SHIV capable of causing
AIDS in pig-tailed macaques. q 1997 Academic Press
obtained by a series of bone marrow– bone marrow pas-Development of effective vaccines against human im-
sages of SHIV-4 in macaques (5, 17). This virus causedmunodeficiency virus type 1 (HIV-1) has been hampered
subtotal depletion of the CD4/ subset of T cells withinin part by the inability of this virus to cause an acquired
4 weeks and AIDS in 70% of pig-tailed macaques withinimmunodeficiency syndrome (AIDS) in nonhuman pri-
8 months (5, 17).mates. As a result, the correlates of immune protection
In this report, we have examined the sequenceagainst HIV-1 infection are still unknown (4). Chimeric
changes in the viral genome obtained from a cell-freesimian– human immunodeficiency virus (SHIV), con-
stock of pathogenic SHIV (SHIVKU-1) that is highly patho-structed with the HXB2 tat, rev, vpu, and env within a
genic for pig-tailed macaques (5). This virus stock wasgenetic background of the pathogenic molecular clone
prepared in mitogen-stimulated macaque peripheralSIVmac239, represents a molecular clone which can be
blood mononuclear cells (PBMC) inoculated with cere-used in a nonhuman primate animal model for identifica-
brospinal fluid (CSF) taken 8 weeks after inoculation oftion of the HIV-1 proteins required to elicit a protective
macaque PNb with fourth passage SHIV (5). For the stud-immune response (8). While this SHIV (designated SHIV-
ies reported here, SHIVKU-1 was inoculated into phytohe-4) caused persistent infection after inoculation into ma-
magglutinin (PHA)-stimulated rhesus macaque PBMC atcaques, these animals did not develop depletion of the
an m.o.i. of approximately 0.01 and incubated for 48 hrCD4/ subset of T cells or AIDS (8, 9). Recently, we de-
at 377. Total cellular DNA was extracted and PCR wasscribed the derivation of a pathogenic variant of SHIV-4
used to amplify the LTR, gag, vif– vpu, env, and nef re-
gions of the viral genome from cellular DNA. Table 1 lists
the various oligonucleotides and their coordinates in the1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (913) 588-5599. SIVmac239 and HXB2 genomes used for PCR amplifica-
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TABLE 1
The Oligonucleotides Used to Amplify the Various Regions of the SHIV Genome
Region of genome Oligonucleotide primer Coordinates
LTR 5*-TGGAAGGGATTTATTACAGTGCAAGAAGAC-3* (sense strand) 1 to 30 (SIVmac239)
5*-TTCTAATTCATCTGCTTTCTTCCCTGA-3* (reverse strand) 1077 to 1103 (SIVmac239)
gag 5*-GGAAGGGGTAATAAGATAGAGTGGGAG-3* (sense strand) 1026 to 1052 (SIVmac239)
5*-ACTTCTACAGGCTGTCCTTCAATATGA-3* (reverse strand) 2593 to 2618 (SIVmac239)
vif, vpx, vpr, tat, rev, vpu 5*-GGGAAGGAGCAGTCATCTTAAAGG-3* (sense strand) 5262 to 5285 (SIVmac239)
5*-CACAAAATAGAGTGGTGGTTGCTTCCT-3* (reverse strand) 6386 to 6413 (HIV/HXB2)
env 5*-ATGAGAGTGAAGGAGAAATATCAGCAC-3* (sense strand) 6224 to 6250 (HIV/HXB2)
5*-TCCACCTCTCCTAAGAGTCTCCCATAAGTC-3* (reverse strand) 9409 to 9439 (SIVmac239)
nef 5*-CCACATACCTAGAAGAATAAGACAGGG-3* (sense strand) 8746 to 8772 (HIV/HXB2)
5*-TCAGCGAGTTTCCTTCTTGTCAGCCAT-3* (reverse strand) 9842 to 9868 (SIVmac239)
tion. One microgram of genomic DNA was used in the SIVmac239 (13) and the HIV-1 tat, rev, vpu, and env se-
quences were compared to the HXB2 (19) sequencesPCR (14, 15) containing 1.4 mM MgSO4 , the four deoxy-
nucleotide triphosphates at 200 mM each, each oligonu- used in the construction of SHIV-4 (8) with PCGENE se-
quence analysis software programs.cleotide primer at 100 pM and a mixture of Taq and
Pyrococcus species GB-D polymerases (Elongase; Gibco The percentage of change in the nucleotide and pre-
dicted amino acid sequences obtained from these clonesBRL). The template was denatured at 947 for 2 min and
PCR amplification was performed with an automated are shown in Table 2. Five clones analyzed for 5* LTR
sequence changes had an average change in their nucle-DNA thermal cycler (Perkin– Elmer Cetus) for 35 cycles
using the following profile: denaturation at 947 for 30 sec, otide sequence of 0.55%. Five consensus changes
were found in the LTR of SHIVKU-1, three of which corre-annealing at 657 for 1 min, and primer extension at 687
for 5 min. Amplification was completed by incubation for sponded to changes in the region of nef that overlaps
the U3 region of the LTR (Fig. 1). The nucleotide changes10 min at 687. Three separate PCRs were performed
for each region of viral genome that was studied. The resulted in an isoleucine to methionine substitution at
position 140, a glutamic acid to lysine substitution atfragments were agarose gel purified and then cloned
into the pGEM-T vector (Promega). Two clones from the position 191, and an arginine to lysine substitution at
position 245 of Nef (Figs. 1 and 2). Two consensusfirst and second PCRs and one or two clones from the
third PCR were sequenced by primer-directed dideoxy changes were found in the TAR region of the LTR, an A
to G substitution at position 544 and C to T substitutionsequencing using Sequenase enzyme (US Biochemicals,
Cleveland, OH) and [35S]dATP. SIVmacLTR, gag, vif, vpr, at position 641. In addition, a T to C substitution was
detected in the tRNA primer-binding site. This substitu-vpx, and nef sequences were compared to the original
TABLE 2
Summary of Genetic Changes in SHIVKU-1a
Total no. of Total no. of Avg. change % nonsilent
No. of nucleotides substitutions Avg. nucleotide in amino acid nucleotide
Region clones sequenced (deletions) substitution (%) sequence (%) substitutions
LTRb 5 5500 30 (0) 0.55 NA NA
gag 5 7700 22 (0) 0.29 0.54 61
vif 5 3210 16 (0) 0.50 0.84 56
vpx 5 1680 4 (0) 0.23 0.53 75
vpr 5 1515 13 (0) 0.86 2.72 100
tat (HIV) 5 1290 17 (0) 1.31 2.32 71
rev (HIV) 5 1725 5 (0) 0.28 0.87 100
vpu 5 1230 10 (0) 1.33 2.17 90
gp120 6 9216 126 (30) 1.04 2.93 83
gp41 5 5190 53 (0) 1.03 1.08 35
nef 5 3945 33 (0) 0.84 2.13 85
a Viral DNA was amplified from tissues by PCR, cloned, sequenced, and compared to the original SHIV sequences.
b Includes the 5* LTR to beginning of the gag gene.
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FIG. 1. Predicted amino acid sequence of the 5* LTR of clones isolated from the SHIVKU-1 stock. Shown above the sequences of the five clones
is the sequence of SIVmac239 5* LTR to the beginning of gag (13). The amino acids corresponding to amino acids 128 to 263 of the Nef whose
gene overlaps the 3* LTR are shown below the nucleotide sequence (nt 1 – 404) of SIVmac239. Dashes (-) represent nucleotide sequence identity.
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FIG. 1— Continued
tion has been observed in an unrelated study of LTR tion at position 17 occurred in the acidic proline-rich
domain of Tat (residues 1– 21), which constitutes partvariation following inoculation of macaques with SIV-
mac239 (data not shown), suggesting that this was not a of the Tat activation domain, whereas the amino acid
substitution in the second exon did not correspond to ansubstitution unique to adaptation of the SHIV-4. The vif,
vpx, and gag had smallest percentage of change in their essential region for Tat function (10).
The rev gene had no consensus changes in the firstnucleotide and predicted amino acid sequences (Table
2). The vpr gene had 0.86 and 2.72% changes in the exon and one consensus nucleotide substitution in the
second exon, resulting in an alanine to serine substitu-nucleotide and amino acid sequences, respectively.
There was a single consensus (glycine to glutamic acid tion at position 68 of Rev. This amino acid substitution
did not occur in the well-defined domains associatedat position 86) in the Vpr protein. Similar to a previous
study (20), we observed that nef had a high percentage with nuclear localization, RNA binding, protein oligomer-
ization, and posttranscriptional activation (10). The vpuof change in the nucleotide (0.84%) and predicted amino
acid (2.13%) sequence (Table 2). There were five consen- gene, which contained an ACG in place of the ATG initia-
tion methionine codon in the HXB2 clone of the originalsus amino acid changes in Nef, an asparagine to aspartic
acid at position 72, a tyrosine to phenylalanine at position nonpathogenic SHIV-4 and thus did not code for a func-
tional Vpu (8), was mutated to a functional ATG in every131, an isoleucine to methionine at position 143, a glu-
tamic acid to lysine at position 191, and an arginine to clone analyzed from SHIVKU-1, and every vpu sequence
analyzed from all tissues of macaque PNb, which diedlysine at position 245 (Fig. 2). Since the 3* region of nef
overlaps the U3 region of the 3* LTR, the changes at of AIDS (data not shown). To confirm that a functional
Vpu protein was expressed from this virus, C8166 cellspositions 190 and 244 were also reflected in the changes
described for the LTR. None of these substitutions corre- were infected either with the pathogenic SHIVKU-1 or with
SHIV-4, and the Vpu protein was immunoprecipitatedsponded to those previously reported to be associated
with the high pathogenicity of SIVsmmPBj14 virus (2). with a Vpu-specific antiserum. As shown in Fig. 3, a
protein with an apparent Mr of 16 kDa was specificallyAnalysis of the HIV-1 genes in this SHIVKU-1 revealed
one consensus nucleotide substitution in the first exon immunoprecipitated from pathogenic SHIV-infected cells
but not from C8166 cells infected with SHIV-4. In additionof tat resulting in a glutamine to lysine substitution at
position 17 of Tat and one nucleotide substitution in the to the reverted ATG codon, every clone analyzed had a
proline to threonine substitution at position 69 of Vpu.second exon of tat resulting in a serine to proline substi-
tution at position 76 in Tat. The basic amino acid substitu- The region of vpu which contains the substitution at posi-
Nucleotides 1 to 30 (*) were not sequenced since they corresponded to the oligonucleotide primer used to amplify this region of the genome.
However, this region was sequenced in the nef clones derived from SHIVKU-1-infected cells (see below). The nucleotide sequence of the PCR-
derived clone PNb2 has been filed with GenBank under Accession No. U89249.
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FIG. 2. Predicted amino acid sequence of nef clones isolated from the SHIVKU-1 stock. Shown above the sequences of the five clones is the
sequence of SIVmac239 nef (13) with nef corrected at codon 92. Dashes (-) represent amino acid identity. The nucleotide sequence of the PCR-
derived clone PNb1 has been filed with GenBank under Accession No. U89248.
tion 69 overlaps the env, but this nucleotide substitution sylation site. The V3 domain of the gp120, previously
shown by other investigators to have linear determinantsbut did not result in an amino acid substitution in the
gp120 of env. for virus neutralization, had a total of 4 consensus
changes (an asparagine to serine, arginine to isoleucine,As expected, the gp120 region of the env gene had
the highest percentage of change in the nucleotide isoleucine to methionine, and asparagine to aspartic acid
at positions 300, 304, 320, and 325, respectively) with the(1.26%) and amino acid sequences (2.93%). Ten consen-
sus amino acid substitutions occurred in the gp120, and substitutions at positions 304 and 325 resulting in basic
to neutral and neutral to acidic amino acid changes, re-8 of these were located in the previously described five
(V1– V5) variable domains (Fig. 4). One consensus substi- spectively. In one-third of the gp120 clones sequenced
(two of six), there was a deletion of five amino acidstution in the V1 domain, a lysine to asparagine at position
130, resulted in the creation of a potential N-linked glyco- (residues 396– 400) in V4. The gp41 region of env con-
tained a lower percentage of change in the nucleotide
(1.03%) and amino acid (1.09%) sequences (Table 2). The
gp41 region of env had a total of 3 consensus amino
acid changes (an asparagine to aspartic acid, isoleucine
to threonine, and isoleucine to threonine substitution at
positions 675, 724, and 782, respectively), with the amino
acid substitution at position 675 resulting in the elimina-
tion of a potential N-linked glycosylation site. None of
the amino acid changes in the gp41 were in the fusion,
putative a-helix/leucine zipper, or immunodominant epi-FIG. 3. Immunoprecipitation analyses demonstrate that Vpu is syn-
thesized in SHIVKU-1-infected cells. 103 TCID50 of SHIV-4 or SHIVKU-1 tope domains (12).
was used to inoculate C8166 cells. At 5 days postinoculation, cells In addition to their association with a pathogenic phe-
were starved for methionine and cysteine and then radiolabeled with notype, the sequence changes were also associated
200 mCi of [35S]methionine and cysteine for 18 hr. Cell lysates were
with altered cell tropism. We analyzed the ability ofprepared as previously described (16) and SHIV proteins were immuno-
SHIVKU-1 to replicate in PHA-stimulated rhesus macaqueprecipitated using a rabbit anti-Vpu serum and protein A– Sepharose
as described in the text. Immunoprecipitates were washed three times PBMC, C8166 cells (a human T cell line), and rhesus
in RIPA buffer and samples were denatured by boiling in SDS –PAGE macrophage cultures. As shown in Fig. 5, both the SHIV-
sample reducing buffer (7). Proteins were separated by SDS – PAGE 4 and the SHIVKU-1 replicated to high titers in both rhesus(8.5% gel) and visualized using standard fluorographic techniques. Lane
PBMC and C8166 cells as determined by the release of1, C8166 cells inoculated SHIV with a corrected initiation codon. Lane
p27 during a 10-day period. Virus production peaked at2, C8166 cells inoculated with the SHIVKU-1 . Lane 3, C8166 cells inocu-
lated with SHIV-4. Lane 4, uninfected C8166 cells. 4 days in the C8166 cells and at 6 days in PHA-stimulated
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FIG. 4. Predicted amino acid sequence of gp120 clones isolated from the SHIVKU-1 stock. Shown above the sequences of the six clones is the
sequence of HXB2 gp120 (19). Dashes (-) represent amino acid identity; crosses (X) represent deletion and asterisks (*) represent premature
termination codons. For comparative purposes, brackets corresponding to the variable regions V1, V2, V3, V4, and V5 were placed above the gp120
sequences. The nucleotide sequences of the PCR-derived clones PNb3, 5, 7, 9, and 10 have been filed with GenBank under Accession Nos. U89247,
U89250, U89251, U89252, and U89253, respectively.
PBMC infected with each virus. Inoculation of rhesus tively infected with each virus. Cultures on coverslips
were stained for the presence of p27 antigen 5 days aftermacrophage cultures prepared from PBMC with either
SHIV-4 or SHIVKU-1 resulted in marked differences in their inoculation with both viruses. As shown in Fig. 6C and
6D, approximately 1– 5% of the cells in cultures inocu-efficiency of replication. Cultures inoculated with SHIVKU-1
produced 15-fold more p27 than did corresponding cul- lated with SHIV-4 stained positive for p27, whereas ap-
proximately 40% of the macrophages in cultures inocu-tures inoculated with SHIV-4. These differences were
also reflected in the number of macrophages produc- lated with SHIVKU-1 stained positive for p27 (Figs. 6E and
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FIG. 5. Growth curve of SHIV-4 and SHIVKU-1 in C8166 cells, PHA-stimulated rhesus macaque PBMC, and rhesus macrophage cultures. Rhesus
macaque PBMC were isolated as described earlier (16) and grown in medium containing PHA for 2 days, at which time 106 cells were infected with
virus and shifted to medium containing PHA/IL2 for 10 days. 106 C8166 cells were infected with virus and maintained as described earlier. Rhesus
macrophages in 35-mm dishes were prepared as described earlier (16). All cultures were inoculated with 250 TCID50 of each virus (an m.o.i. of
approximately 0.00025) for 24 hr, washed three times to remove the virus inoculum, and maintained in the appropriate medium for the course of
infection. Culture medium was harvested at the time points indicated and assayed for the presence of p27 antigen using antigen capture assays
(Coulter Corp.). (s) SHIV-4-infected C8166 cells. (l) SHIVKU-1-inoculated C8166 cells. (n) SHIV-4-inoculated rhesus PBMC. (m) SHIVKU-1-inoculated
rhesus PBMC. (h) SHIV-4-inoculated rhesus macrophage cultures. (j) SHIVKU-1-inoculated rhesus macrophages.
FIG. 6. Immunocytochemistry demonstrates that SHIV-4 is lymphocyte-tropic and that SHIVKU-1 is macrophage-tropic. Macaque macrophage cultures
were infected with either SHIV-4 or PNbCSF SHIV. At 5 days following inoculation, cells were washed, fixed, and stained for p27 antigen as previously
described (16). Cells that stain positive have a brown color when compared to the background. (A) Uninfected macrophage culture, 1001. (B) Uninfected
macrophage culture, 4001. (C) Macrophage culture infected with SHIV-4, 1001. (D) Macrophage culture infected with SHIV-4, 4001. (E) Macrophage
culture infected with SHIVKU-1 , 1001. (F) Macrophage culture infected with SHIVKU-1 , 4001.
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(gp160) proteins were similar in macrophage cultures
inoculated with either SHIV-4 or SHIVKU-1 ; however, the
processing of the gp160 appeared to be less efficient in
SHIV-4 infected cultures. Further, radiolabeled gp120
was not released into the culture medium of infected
cells (Fig. 7). In contrast, the SHIVKU-1 precursor proteins
(gp160 and p57) were efficiently synthesized, and the
mature cleavage products (gp120 and p27) were re-
leased efficiently into the culture medium of infected cells
(Fig. 7). Taken together, these three independent assays
(p27 release from infected cultures, immunostaining of
macrophage cultures, and processing of viral glycopro-
teins) indicated that the SHIVKU-1 has acquired macro-
phage-tropic properties. Previous studies have shown
that the determinants for macrophage tropism of HIV-1
strains can be mapped to either V3-dependent and/or
V3-independent amino acid substitutions (1, 3, 6, 11, 18).
FIG. 7. Immunoprecipitation analyses demonstrate that the SHIVKU-1 This suggests that macrophage tropism is defined by
Env and Gag precursors are more efficiently processed in macrophage complex interactions among different regions of the Env
cultures. 103 TCID50 of SHIV-4 or SHIVKU-1 was used to inoculate cul- protein or that multiple mechanisms are involved with
tures of rhesus macrophages as previously described (16). At 5 days
the adaptation of HIV-1 strains to replicate productivelypostinoculation, cells were starved for methionine and cysteine and
in macrophage cultures. SHIVKU-1, which clearly had un-then radiolabeled with 200 mCi of [35S]methionine and cysteine for 18
hr. The culture medium was harvested and cell lysates were prepared. dergone conversion from a lymphocyte-tropic virus to
SHIV proteins were immunoprecipitated using serum from macaque a dual-tropic virus, contained none of the amino acid
PNb and protein A–Sepharose as described in the text. Immunoprecipi- substitutions in the V3 domain previously shown to be
tates were washed three times in RIPA buffer and samples were dena-
involved in determining macrophage tropism of certaintured by boiling in SDS – PAGE sample reducing buffer. Proteins were
HIV-1 strains. This may reflect an adaptation of theseparated using SDS – PAGE (8.5% gel) (7) and visualized using stan-
dard autoradiographic techniques. The left blot represents SHIV pro- SHIVKU-1 to grow in rhesus macrophages, since this virus
teins immunoprecipitated from cell lysates, while the on the right are replicates poorly in human macrophages (data not
shown SHIV proteins immunoprecipitated from the culture medium. shown).
(Left) Lane 1, uninfected rhesus macrophages. Lane 2, proteins immu-
The results presented here indicate that the SHIV origi-noprecipitated from rhesus macrophages infected with SHIV-4. Lane
nally constructed with the tat, rev, vpu, and env of the3, proteins immunoprecipitated from rhesus macrophages infected with
SHIVKU-1 . (Right) Lane 1, uninfected rhesus macrophages. Lane 2, pro- HXB2 strain of HIV-1 underwent a limited number of nu-
teins immunoprecipitated from rhesus macrophages infected with cleotide and amino acid substitutions in the SIVmac239
SHIV-4. Lane 3, proteins immunoprecipitated from rhesus macro- and HIV-1 regions of the virus genome when it became
phages infected with SHIVKU-1 . virulent. While the majority of the consensus substitu-
tions were found in env and nef, other substitutions were
observed in the LTR, vpr, and vpu. Particularly significant6F). Notably, both of these viruses caused minimal cyto-
pathic effects in macrophage cultures. Previously, we was the nucleotide substitution in vpu, which converted
the nonfunctional vpu of SHIV-4 into one capable of di-had shown that the glycoprotein precursor of lympho-
cyte-tropic SIVmac239 was inefficiently processed in rhe- recting the synthesis of a functional protein in SHIVKU-1
(Fig. 1). In a previous study, it was determined that thesus macrophages, whereas the corresponding protein
of macrophage-lytic SIVmac239/17E was very efficiently conversion of the ACG codon in the nonfunctional vpu
of SHIV-4 to an ATG did not result in a virus pathogenicprocessed with cytopathic effects in similar cultures (16).
We examined the processing of the viral Gag and Env for macaques (9), suggesting that reversion of the vpu
alone is not the sole determinant of pathogenicity ofprotein precursors following inoculation onto rhesus
macrophage cultures. These cultures were inoculated SHIV. Our findings that all macaques dying with AIDS
during an 8-month period after inoculation with SHIVKU-1with 103 TCID50 of the SHIV-4 or SHIVKU-1 and at 5 days
postinfection, cells were starved for methionine and cys- had an open vpu gene (data not shown) suggest that the
conversion of vpu into a functional gene may have beenteine and then radiolabeled as previously described (16).
The culture medium was retained and cell lysates were one of the substitutions required for conversion to a
pathogenic virus. The observations in this study indicateprepared for radioimmunoprecipitation as described pre-
viously, and SHIV-specific proteins were immunoprecipi- that nucleotide substitutions (and their corresponding
amino acid changes) occurred in several viral genes,tated using the antiserum from macaque PNb (5, 16). As
shown in Fig. 7, the levels of precursor Gag (p57) and Env suggesting that adaptation of SHIV-4 to pathogenic
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